For Q2, Domestic Core revenues increased ~8%, International Core revenues increased ~17%, and Novel Therapies revenues declined ~28%, the company said.
Full-year 2023 net revenues are now expected to be between $31 million and $32.5 million. The consensus estimate is $32.62 million.
“The company’s guidance for full year 2023 has been updated to reflect a Q2 2023 decline in the U.S. subcutaneous immunoglobulin market, resulting in a change of KORU Medical’s outlook on underlying U.S. core market growth assumption from 10% to the mid-single digit range,” KORU said.
The cash balance was $11.7 million as of June 30, 2023.
The company said it is reaffirming an expected end-of-year cash balance greater than $10.0 million.
Full-year gross margins are expected to be between 58–60%, with an exit rate of around 60–62%.
Shares -3.2% at $2.40 after hours.
